What Avere Therapeutics does

Avere Therapeutics is a clinical-stage biotechnology company headquartered at 2001 Market Street, Suite 2500, Philadelphia, Pennsylvania, with its corporate agreement governed under the laws of the Commonwealth of Massachusetts. The company is developing AVR-001, an oral, once-weekly interleukin-23 (IL-23) receptor antagonist positioned for the treatment of chronic inflammatory diseases including psoriasis, ulcerative colitis, Crohn's disease, and psoriatic arthritis. The core technical differentiator is the dosing profile: an oral small molecule administered once weekly rather than the injectable biologics that currently dominate the IL-23 inhibitor class, targeting improved adherence and patient convenience in chronic indications.

The company operates as a single-asset, pre-commercial developer with no approved products and no disclosed revenue. Its business model is the standard clinical-stage biotech path: advance AVR-001 through clinical development to regulatory approval, then commercialize either directly via specialty pharma distribution to physicians and payers, or via partnership/out-licensing of regional or global rights. No pricing model, payer strategy, or commercial channel is disclosed in the available data, and no manufacturing footprint or supply-chain architecture is referenced.

The most significant strategic event in the input is the announced merger in which Avere will acquire NextCure, a publicly traded NASDAQ-listed company (ticker reference IRX4G3), for an undisclosed amount, with a target close of 2026-07-14. The transaction is positioned to broaden Avere's corporate platform and provide public-market access for clinical execution. The company is privately held, no funding rounds or capital raises are disclosed, and no executive team or headcount data is provided in the input.

Name

Avere Therapeutics

Legal name

Avere Therapeutics

Website

https://averetx.com

Company type

Private

Founded year

2026

Operating status

Operating

Headcount range

1–10 employees

Short description

Avere Therapeutics is a clinical-stage biotechnology company developing AVR-001, an oral once-weekly IL-23 receptor antagonist for chronic inflammatory diseases including psoriasis, ulcerative colitis, Crohn's disease, and psoriatic arthritis.

Ownership category

akta.pro rank

Product category

Inflammatory Disease Biopharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB)

akta.pro secondary industry

Immunology & Inflammation Pharmaceuticals (HLAIAAAD)

Keywords

• IL-23 receptor antagonist
• Inflammatory disease therapy
• Oral biologic therapy
• Clinical-stage biopharmaceutical
• Immunology drug development

Headquarters

HQ city

Conshohocken

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Pharmaceutical Product Revenue: Pre-revenue clinical-stage biotech. The company is developing AVR-001 for inflammatory diseases (psoriasis, ulcerative colitis, Crohn's disease, psoriatic arthritis). Revenue will be generated through prescription drug sales upon FDA approval and commercialization.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Avere Therapeutics is developing AVR-001, a single clinical-stage oral, once-weekly interleukin-23 receptor antagonist (IL-23RA) intended for the treatment of chronic inflammatory diseases including psoriasis, ulcerative colitis, Crohn's disease, and psoriatic arthritis. The candidate is engineered for higher, more consistent drug exposure and a longer half-life to enable once-weekly oral dosing as an alternative to injectable IL-23 inhibitors. The company is pre-revenue and has no commercialized products as of the source data.

Product overview

Avere Therapeutics is developing a single pharmaceutical product, AVR-001, an oral once-weekly IL-23 receptor antagonist. The company is focused on advancing this single drug candidate through clinical development for inflammatory diseases including psoriasis, ulcerative colitis, Crohn's disease, and psoriatic arthritis. The product represents a potentially meaningful improvement in treatment through its convenient once-weekly pill format.

Differentiator

Problem solved

Functional benefit

Products and services

• AVR-001 AVR-001 is an oral, once-weekly interleukin-23 receptor antagonist (IL-23RA) in clinical development for chronic inflammatory diseases including psoriasis, ulcerative colitis, Crohn's disease, and psoriatic arthritis. It is engineered for higher, more consistent drug exposure and a longer half-life to enable weekly oral dosing as an alternative to injectable IL-23 inhibitors.

Segments1 record

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

One partnership is on record.

• NextCureflagshipStrategic or Co-development Partner · 1 January 2025NextCure and Avere Therapeutics announced a merger to advance the once-weekly oral IL-23 therapy (AVR-001). This strategic combination is designed to accelerate development of AVR-001, combining NextCure's capabilities with Avere's IL-23 inhibition technology platform. The merger represents a significant corporate development milestone for the combined entity.

Scale indicators1 record

Recent moves2 records

Expansion highlights3 records

Emerging players

• Pfizer: Pfizer markets Velsipity (etrasimod), an oral S1P receptor modulator approved for ulcerative colitis, and has a broader immunology pipeline. It is an oral immunology peer whose commercial footprint in IBD will overlap with any future AVR-001 positioning.
• Galapagos NV: Galapagos has historically pursued oral immunology candidates (e.g., JAK and S1P programs) in IBD and inflammatory diseases. As a European specialty biotech focused on oral small-molecule immunology, it is an emerging peer whose development path and commercial scale are comparable to Avere's anticipated trajectory.
• Bristol Myers Squibb: BMS markets Zeposia (ozanimod), an oral S1P modulator approved for ulcerative colitis and Crohn's disease, and is developing next-generation oral immunology candidates. It represents the oral immunology convenience benchmark Avere's oral IL-23 must compete against in IBD.

Broad incumbents

• Roche: Roche markets Actemra (tocilizumab) and has a broad immunology franchise including IL-pathway biologics. As a global immunology leader with deep commercial reach in psoriasis and IBD, Roche is a relevant broad incumbent shaping the standards Avere's therapy must exceed.
• Takeda Pharmaceutical: Takeda markets Entyvio (vedolizumab), a leading biologic for ulcerative colitis and Crohn's disease, and is a major IBD commercial player. While not an IL-23 program, Entyvio defines the IBD treatment paradigm Avere's oral IL-23 must position against.

Direct peers

• Sun Pharmaceutical Industries: Sun Pharma markets Ilumya/Tildrakizumab, an approved IL-23 inhibitor for psoriasis and active psoriatic arthritis. As an established injectable competitor in Avere's lead dermatology indication, it shapes the competitive landscape Avere must enter.
• Johnson & Johnson: Johnson & Johnson markets Tremfya (guselkumab), an approved IL-23 inhibitor in psoriasis, psoriatic arthritis, Crohn's, and ulcerative colitis, and is Protagonist's partner on the oral IL-23 peptide icotrokinra — making J&J both a direct injectable competitor and the steward of the most advanced oral IL-23 program competing with AVR-001.
• Eli Lilly: Eli Lilly markets Omvoh (mirikizumab), an approved IL-23p19 inhibitor for ulcerative colitis and Crohn's disease. It directly competes in Avere's IBD target indications and represents the kind of large-pharma incumbent Avere will face commercially.
• AbbVie: AbbVie markets Skyrizi (risankizumab), an approved IL-23 inhibitor for psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. It is the largest commercial incumbent in Avere's exact target indications and the benchmark Avere must beat on efficacy, safety, and convenience.
• Protagonist Therapeutics: Protagonist Therapeutics is developing icotrokinra (JNJ-2113), an oral IL-23 receptor antagonist peptide partnered with Johnson & Johnson — the most direct competitor to AVR-001 given both programs pursue oral IL-23 inhibition for psoriasis and other inflammatory diseases.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat2 records

Key risks5 records

Key highlights5 records

Customer concentration

• LinkedInlinkedin.com/company/avere-therapeutics

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds1 record

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Avere Therapeutics